SBIR/STTR Research Award

PROTECT: optima4BP 2.0: prediction of Optimal Treatment and Route to achieve and maintain BP Target

Award identifier b629587cafe1ea42d4b28400daa941d2fd35f0805aaf8ad66eb999d4fdf7306fAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,466,232

Program and phase

SBIR · Phase II

Award year

2020

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
OPTIMA INTEGRATED HEALTH, INC.
Proposal award date
2020-05-15
Contract end date
2022-04-30
UEI
ZD6UHHHXNYN8
Solicitation number
PA18-574
Topic code
NHLBI

Research abstract

Need. In the US, 40 million patients with hypertension (HTN) have their blood pressure (BP) uncontrolled. BP above clinical Target even for a few months increases the risk for stroke (35-40%), heart failure (HF) (up to 64%), myocardial infarction (MI) (15-25%). Physician-nurse-pharmacist resource-intensive demonstrations in achieving andamp; maintaining BP Target have shown promising results, but their real-life deployment was found unsustainable long-term. As a result, a process-standardized and sustainable solution is acutely needed.Solution. In response to this need, Optima Integrated Health developed optima4BP 1.0. It is a first-in-class artificial intelligence (AI) that simulates the process of clinical reasoning undertaken by the treating physician in optimizing the anti-HTN treatment towards BP Target. Just like the physician, optima4BP 1.0 cannot determine upfront the needed Optimal Treatment (OT) to achieve andamp; maintain BP Target for 1-2 years. PROTECT [optima4BP 2.0: prediction of Optimal Treatment and route to achieve and maintain BP Target] proposes to establish upfront the personalized OT. The OT can then be used to select the shortest and safest treatment modification route needed to achieve andamp; maintain BP Target. Phase II Goal. Build optima4BP 2.0.Phase I. Phase I Prior Work demonstrated that k-Nearest Neighbor (kNN), an AI model, can predict with ≥ 80% confidence the correct anti-HTN treatment, when compared to physician decision.Phase II. optima4BP 2.0 will predict the Optimal Treatment and route to achieve andamp; maintain BP Target.Optimal Treatment data-mining source. PROTECT will use the SPRINT (Systolic Blood Pressure Intervention Trial, 2015) and ACCORD (Action to Control Cardiovascular Risk in Diabetes, 2010) clinical trial data. They represent the foundation of the most current anti-HTN treatment management national guidelines.Aim 1. Build kNN. Hypothesis. kNN can predict the proximity (clinical relevance) of a patient to an Optimal Treatment (OT). Milestone. Achieve ≥ 90% accuracy of prediction to physician decision. Phase I Data Preparation protocol will be applied to the SPRINT andamp; ACCORD data. Then, the kNN Ensemble Learning function will be built to select the Optimal Treatment with the highest demonstrated efficacy by comparing the choice from 3 computational approaches developed and tested during Phase I.Aim 2. Build the Optimal Treatment Route (OTR). Hypothesis. Knowing the Current and Optimal Treatment (OT), an OTR can be built. Milestone. Safest Route: Achieve 100% exclusion of treatments that led to an adverse event in similar patient populations. Shortest Route: Achieve ≥30% reduction in number of treatment changes compared to physician route. The OTR will be built by comparing at each Step on the Route how similar each Candidate Treatment is to the OT through a computed similarity assessment.optima4BP 2.0 aims to establish a process-standardized andamp; sustainable solution with the goal of reducing the incidence of stroke, HF, MI and death resulting from uncontrolled hypertension.In the US, 40 million patients with hypertension have their blood pressure uncontrolled. We propose to build and test optima4BP 2.0 (Project Name: PROTECT) that will predict upfront the personalized optimal treatment and shortest treatment route required by a patient to achieve and maintain blood pressure target. Achieving and maintaining blood pressure target will reduce the incidence of adverse events [stroke (35-40%), heart failure (up to 64%), myocardial infarction (15-25%)] or death resulting from uncontrolled hypertension.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

6 SBIR/STTR records share this UEI (2017–2022). Reported award amounts total $7,090,025. Reported amounts are not federal obligations.

Phases: Phase II – Direct to Phase II, Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.